Board of Directors

Beth Altman

Chair of the Audit Committee

• 27+ years of experience in finance, management, business, accounting and internal controls
• Former managing partner at KPMG LLP San Diego
• Former KPMG LLP audit partner serving early-stage start-ups through complex public global corporations
• Advisor to companies on capital raises, initial public offerings, M&A and corporate governance matters

Mark Beer

Chairman

• • 30+ years development and commercialization experience
• Executive Chairman of BioTE Medical Inc
• Founder of Renovia Inc
• Former CEO of Aegerion Pharmaceuticals Inc (AEGR)
• Founder of Viacell Inc (VIAC) which got sold to Perkin Elmer (PKI) Inc Beecham

Paul Blake, FRCP

Founder & CEO

• 30+ years management and drug development experience
• Numerous NDA/sNDA/MAA approvals, including three entirely novel indications
• Former Chief Development Officer at Oxford Biomedica
• Former Executive VP of Worldwide Medical and Regulatory Operations at Cephalon
• Former Chief Medical Officer and Senior VP of Clinical R&D at SmithKline Beecham

Hani Gabra, PhD FRCP

Founder & CSO

• Internationally-recognized translational medical oncologist and gynecologic cancer expert with 30+ years of academic experience
• Professor Emeritus in Medical Oncology at Imperial College London
• Visiting Professor at the Center for Cancer Biomarkers at University of Bergen
• Former VP in early clinical development at Astra Zeneca
• Former CMO and head of clinical development at BerGenBio AS

Jim Lorens, PhD

Chair, Scientific Advisory Board

• 35+ years academic research and biotech industry experience across the US and Europe
• Head of Oncology and Founding Scientist at Rigel Pharmaceuticals Inc (RIGL)
• Founder of BerGenBio AS
• Professor in the Department of Biomedicine at the University of Bergen Faculty of Medicine
• Developed the first AXL targeting agent into the clinic